Astellas Pharma US, Inc. Selects Dendrite for Sample Compliance Solutions; Dendrite's Robust and Intuitive Compliance Solutions

Dendrite International, Inc., (NASDAQ: DRTE) a leading
provider of pharmaceutical industry solutions, today announced that
Astellas Pharma US, Inc., a pharmaceutical company dedicated to
improving the health of populations around the world, signed a
three-year contract to outsource its sample accountability and
compliance processes to Dendrite.
   Dendrite's market-leading Compliance Solutions division will
manage Astellas Pharma US Inc.'s compliance requirements using several
components of its comprehensive solution offering. This includes
reconciliation services, web-based reporting and trending services,
inventory and audit services, and sales representative closeouts,
enabling the Astellas' US sales force of more than 500 sales
representatives to remain compliant with Prescription Drug Marketing
Act (PDMA) requirements.
   "Dendrite came out on top in our evaluation of companies that
could meet our immediate and long term needs for sample management and
compliance. Their reputation and capabilities are strong, and we're
confident they will continue to provide value as we progress in our
relationship," said Kathy Pettinato, associate director Sampling
Operations at Astellas.
   "Our compliance solutions are designed to decrease the
administrative burden associated with the accountability of drug
samples while enhancing compliance levels," said Bill Buzzeo, vice
president and general manager Dendrite Compliance Solutions division.
"As Astellas continues to grow, it is critical for them to have the
most sophisticated, yet highly intuitive sample accountability and
compliance solutions available."

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   About Astellas Pharma US, Inc.

   Astellas Pharma US, Inc., located in Deerfield, Illinois, is a US
affiliate of Tokyo-based Astellas Pharma Inc., Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
pharmaceutical products. The organization is committed to becoming a
global pharmaceutical company by combining outstanding R&D and
marketing capabilities and continuing to grow in the world
pharmaceutical market. For more information about Astellas Pharma US,
Inc., please visit our website at www.astellas.com/us.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.